Patient and parent preferences for characteristics of prophylactic treatment in hemophilia
Open Access
- 1 November 2015
- journal article
- research article
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. 9, 1687-1694
Abstract
Introduction: New longer-acting factor products will potentially allow for less frequent infusion in prophylactic treatment of hemophilia. However, the role of administration frequency relative to other treatment attributes in determining preferences for prophylactic hemophilia treatment regimens is not well understood. Aim: To identify the relative importance of frequency of administration, efficacy, and other treatment characteristics among candidates for prophylactic treatment for hemophilia A and B. Method: An Internet survey was conducted among hemophilia patients and the parents of pediatric hemophilia patients in Australia, Canada, and the US. A monadic conjoint task was included in the survey, which varied frequency of administration (three, two, or one time per week for hemophilia A; twice weekly, weekly, or biweekly for hemophilia B), efficacy (no bleeding or breakthrough bleeding once every 4 months, 6 months, or 12 months), diluent volume (3 mL vs 2.5 mL for hemophilia A; 5 mL vs 3 mL for hemophilia B), vials per infusion (2 vs 1), reconstitution device (assembly required vs not), and manufacturer (established in hemophilia vs not). Respondents were asked their likelihood to switch from their current regimen to the presented treatment. Respondents were told to assume that other aspects of treatment, such as risk of inhibitor development, cost, and method of distribution, would remain the same. Results: A total of 89 patients and/or parents of children with hemophilia A participated; another 32 were included in the exercise for hemophilia B. Relative importance was 47%, 24%, and 18% for frequency of administration, efficacy, and manufacturer, respectively, in hemophilia A; analogous values were 48%, 26%, and 21% in hemophilia B. The remaining attributes had little impact on preferences. Conclusion: Patients who are candidates for prophylaxis and their caregivers indicate a preference for reduced frequency of administration and high efficacy, but preferences were more sensitive to administration frequency than small changes in annual bleeding rate.Keywords
This publication has 36 references indexed in Scilit:
- Health‐related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti‐inhibitor complex concentrate: results from the Pro‐FEIBA studyHaemophilia, 2013
- Patient‐reported outcomes of 182 adults with severe haemophilia in Germany comparing prophylactic vs. on‐demand replacement therapyHaemophilia, 2013
- Health‐related quality of life in haemophilia patients with inhibitors and their caregiversHaemophilia, 2012
- Prophylaxis in Children with Hemophilia: Evidence-Based Achievements, Old and New ChallengesSeminars in Thrombosis and Hemostasis, 2012
- Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of lifeEuropean Journal of Haematology, 2012
- Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimensHaemophilia, 2009
- Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapyJournal of Thrombosis and Haemostasis, 2009
- Primary prophylaxis in children with haemophilia2008
- Comparing outcomes of different treatment regimens for severe haemophiliaHaemophilia, 2003
- Health status and health‐related quality of life associated with hemophiliaAmerican Journal of Hematology, 2002